NCT00724841View on ClinicalTrials.gov

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2010

Conditions
Metastatic Melanoma
Interventions
DRUG

Obatoclax Mesylate

Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

DRUG

Temozolomide

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Lead Sponsor

Gemin X
All Listed Sponsors
lead

Gemin X

INDUSTRY

NCT00724841 - A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma | Biotech Hunter | Biotech Hunter